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Abstract: A score system integrating the evolution of efﬁ cacy and tolerability over time 
was applied to a subpopulation of the STRATHE trial, a trial performed according to a paral-
lel group design, with a double-blind, random allocation to either a ﬁ xed-dose combination 
strategy (perindopril/indapamide 2 mg/0.625 mg, with the possibility to increase the dose to 
3 mg/0.935 mg, and 4 mg/1.250 mg if needed, n = 118), a sequential monotherapy approach 
(atenolol 50 mg, followed by losartan 50 mg and amlodipine 5 mg if needed, n = 108), or a 
stepped-care strategy (valsartan 40 mg, followed by valsartan 80 mg and valsartan 80 mg+ 
hydrochlorothiazide 12.5 mg if needed, n = 103). The aim was to lower blood pressure below 
140/90 mmHg within a 9-month period. The treatment could be adjusted after 3 and 6 months. 
Only patients in whom the study protocol was strictly applied were included in this analysis. At 
completion of the trial the total score averaged 13.1 ± 70.5 (mean ± SD) using the ﬁ xed-dose 
combination strategy, compared with –7.2 ± 81.0 using the sequential monotherapy approach 
and –17.5 ± 76.4 using the stepped-care strategy. In conclusion, the use of a score system allows 
the comparison of antihypertensive therapeutic strategies, taking into account at the same time 
efﬁ cacy and tolerability. In the STRATHE trial the best results were observed with the ﬁ xed-dose 
combination containing low doses of an angiotensin enzyme converting inhibitor (perindopril) 
and a diuretic (indapamide).
Keywords: antihypertensive therapy, tolerability, antihypertensive efﬁ cacy, ﬁ xed-dose com-
bination, sequential monotherapy, stepped-care treatment
Introduction
During the last few decades numerous clinical trials have been performed in the ﬁ eld 
of hypertension. These trials were required for the development of new antihyper-
tensive agents and to demonstrate their efﬁ cacy and tolerability in comparison with 
placebo or established blood-pressure-lowering agents. Pharmacological treatment 
of hypertension has been shown over the years to decrease signiﬁ cantly morbidity 
and mortality due to cardiovascular and renal diseases (Staessen et al 2003; Turnbull 
et al 2005; Williams 2005). Today it appears critical to achieve strict blood pressure 
control in hypertensive patients in order to provide maximum beneﬁ t from blood 
pressure lowering, and current guidelines recommend bringing blood pressure below 
140/90 mmHg in every patient, and even below 130/80 mmHg if high blood pressure 
co-exists with diabetes mellitus and/or renal disease (Chobanian et al 2003; Mancia 
et al 2007). Different therapeutic strategies are available to reach these goal blood 
pressures, but increasing evidence indicates that the combination of two or more 
drugs is needed in most patients (Brunner et al 1990; Dusing 2006). In terms of 
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pharmacological treatment of hypertension, the ideal drug 
regimen should be effective, well tolerated, and easy to 
take every day, thereby facilitating long-term adherence. To 
what extent a given treatment fulﬁ lls these criteria remains, 
however, difﬁ cult to assess in clinical trials.
The present study was aimed to evaluate whether a score 
system integrating the evolution of efﬁ cacy and tolerability 
over time would enable a better characterization of advan-
tages and disadvantages of antihypertensive drug regimens. 
To this end we created a score system and applied it to the 
STRATHE trial, a parallel group design trial which compa-
red in double-blind fashion different therapeutic strategies 
(Mourad et al 2004).
Patients and methods
The STRATHE study was performed in France by 193 com-
munity physicians in 533 patients with a mean sitting systolic 
blood pressure 160 mmHg and/or a mean diastolic blood 
pressure 95 mmHg after a 4-week single-blind placebo 
run-in. After randomization to a ﬁ xed low-dose combina-
tion (perindopril/indapamide, 2 mg/0.625 mg, increased if 
required ﬁ rst to 3 mg/0.937 mg and later to 4 mg/1.25 mg) 
(n = 180 ), sequential monotherapy (atenolol 50 mg, followed 
as needed ﬁ rst by losartan 50 mg, and then by amlodipine 
5 mg) (n = 176 ), or stepped care (valsartan 40 mg, increased 
if necessary ﬁ rst to valsartan 80 mg, with the possibility to 
combine then valsartan 80 mg and hydrochlorothiazide, 
12.5 mg (n = 177) (Mourad et al 2004). In each study arm 
the aim was to lower blood pressure below 140/90 mmHg. 
To this end, the treatment could be adjusted as described 
above after 3 and 6 months of therapy. The ﬁ nal visit was 
planned after 9 months of treatment, or at 6 months if tar-
get blood pressure was achieved. Upgrading to a superior 
level was recommended when systolic blood pressure was 
140 and 160 mmHg and/or diastolic blood pressure 
90 mmHg, and 95 mmHg, but was mandatory when 
systolic pressure was 160 mmHg and/or diastolic blood 
pressure 95 mmHg. There was, however, still the possibi-
lity, regardless of the blood pressure achieved, to maintain 
the previous level if the investigators were concerned about 
treatment upgrading, for safety reasons. Blood pressure was 
measured in the sitting position using a mercury sphygmo-
manometer. Three readings were obtained at each visit, with 
at least a 1-min interval between each reading, and were then 
averaged. All study tablets were encapsulated to conceal their 
identity and had to be taken once a day in the morning.
The present analysis included patients having still 
their blood pressure (BP) in whom the study protocol 
was strictly applied, which means that the treatment was 
modiﬁ ed according to the randomized therapeutic strategies 
each time blood pressure was still 140/90 mmHg (ﬁ xed 
low-dose combination, n = 118; sequential monotherapy, 
n = 108 ; stepped-care approach, n = 103). A score system 
was created to assess the advantages and the disadvantages 
of the treatment approaches. The number of points was 
attributed in order to give equal importance to efﬁ cacy and 
tolerability in comparing the different therapeutic strategies 
as follows:
Month 3: BP 140/90 mmHg = +25
  BP 140/90 mmHg = –25
  side-effect(s) during months 1–3 = –25
Month 6: BP 140/90 mmHg = +25
  BP 140/90 mmHg = –25
  side-effect(s) during months 3–6 = –25
Month 9: BP 140/90 mmHg = +50
  BP 140/90 mmHg = –50
  side-effect(s) during months 6–9 = –25
At any time: withdrawal because of side-effect(s) = –50
Data are reported as means ± SD. The scores calculated 
as described above were not subjected to statistical analysis 
since they were not predeﬁ ned endpoints (Mourad et al 
2004). Also, this study includes only the subset of patients 
who underwent changes in therapy during the trial each time 
their blood pressure was still 140 mmHg for systolic and/or 
90 mmHg for diastolic.
Results
The fraction of patients who normalized their blood pressure 
(140/90 mmHg) during the 9 month follow-up was 72.9% 
in the ﬁ xed low-dose combination group, compared with 
59.3% and 52.4% in the sequential monotherapy and stepped-
care groups, respectively. Table 1 shows the percentage of 
patients in the three treatment groups who normalized their 
blood pressure during the course of the trial (Months 3, 6 
and 9).
Figure 1 shows the percentage of patients exhibiting a 
cumulative positive, neutral (sum of positive and negative 
points = 0), or negative score at completion of the trial. A 
positive score was achieved more often using the ﬁ xed low-
dose strategy (64.4%) than using the sequential monotherapy 
(51.9%) or the stepped-care (43.7%) approach.
During the course of the trial the score increased by an 
average of 13.1 ± 70.5 points in the ﬁ xed low-dose combi-
nation group, but decreased by 7.2 ± 81.0 and 17.5 ± 76.4 
points in the sequential monotherapy and stepped-care 
groups, respectively.
Vascular Health and Risk Management 2008:4(1) 251
A score system to evaluate antihypertensive therapy
Discussion
Controlled clinical trials are critical for characterizing the 
efﬁ cacy and the tolerability of new antihypertensive agents. 
This has been done, for instance, during the developmental 
phase of the ﬁ xed low-dose combination containing the 
angiotensin converting enzyme inhibitor perindopril and 
the diuretic indapamide (Laurent 2001). In addition mor-
bidity and mortality trials should be performed whenever 
possible to deﬁ ne the most appropriated indications of each 
class of antihypertensive drugs (Williams 2005; Zanchetti 
2005). During recent years the importance of bringing blood 
pressure below 140 mmHg for systolic and 90 mmHg for 
diastolic has been emphasized (Chobanian et al 2003; Man-
cia et al 2007). To achieve these target blood pressures the 
co-administration of two drugs is often required, accounting 
for the growing interest for ﬁ xed-dose combinations (Brun-
ner et al 1990; Dusing 2006). The advantage of combining 
drugs acting by different mechanisms in a single pill is to 
enhance the antihypertensive efﬁ cacy, but not at the expense 
of reduced tolerability (Law et al 2003), and to facilitate 
long-term persistence on treatment (Van Wijk et al 2005). 
There is therefore a strong rationale for the use of ﬁ xed-dose 
combinations not only as second-line, but also as ﬁ rst-line 
therapy (Elliott 2002; Welsh and Ferro 2004), and this view 
has been supported by international experts in hypertension 
guidelines (Chobanian et al 2003: Mancia et al 2007).
Beyond combination therapy as ﬁ rst step, the traditional 
strategies for treating hypertension with drugs comprise the 
stepped-care approach (monotherapy as initial treatment, 
followed if needed by a dose titration or the addition of 
a second drug) and the sequential monotherapy approach 
(rotation through several monotherapies from different 
classes until blood pressure control is reached) (Brunner 
et al 1990). The design of the STRATHE trial is original as 
it enabled, under controlled conditions, a direct comparison 
of different therapeutic strategies in clinical practice (Mourad 
Table 1 Percentage of patients having their blood pressure normalized (140/90 mmHg) at months 3, 6, and 9
 Fixed-dose  Sequential  Step by step 
 combination(n = 118) monotherapy (n = 108) strategy (n = 103)
Month 3 59.8% 60.4% 43.6%
Month 6 69.2% 61.5% 53.5%
Month 9 72.9% 59.3% 52.4%
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Figure 1 Fraction of patients exhibiting a cumulative positive, neutral or negative score at the end of the trial.
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et al 2004). A ﬁ rst-line management of essential hypertensive 
patients based on a low-dose combination of perindopril and 
indapamide normalized blood pressure (140/90 mmHg) in 
signiﬁ cantly more patients (62%) than a sequential mono-
therapy strategy involving atenolol, losartan, and amlodipine 
(49%), and a stepped-care strategy involving valsartan and 
hydrochlorothiazide (47%), without difference, however, 
between the three groups with regard to the tolerability 
proﬁ le. The blood pressure normalization rate observed in 
the subset of patients of the STRATHE trial included in the 
present analysis is even better (72.9% in the ﬁ xed low-dose 
combination group, 59.3% in the sequential monotherapy 
group, and 52.4% in the stepped-care group). These patients 
were selected as their treatment was modiﬁ ed according 
to the study protocol at each visit if their blood pressure 
was still 140/90 mmHg, indicating that it is important to 
adjust antihypertensive treatment if blood pressure remains 
uncontrolled.
The choice of the most appropriate strategy to treat hyper-
tensive patients is still difﬁ cult. To be considered are efﬁ cacy 
or tolerability criteria, as well as the presence of target organ 
damage or associated cardiovascular/renal disorders. Some 
drug regimens may require fewer adjustments than others at 
initiation of treatment, an advantage derived from a better 
antihypertensive efﬁ cacy combined with a preserved tolera-
bility. The turbulence resulting from treatment adjustments 
might have important implications. In addition to a negative 
economic impact, frequent drug switches might lead patients 
to become non-compliant, or even to stop the treatment 
(Hughes and McGuire 1998; Dusing 2001; Urquhart 2001). 
Notably, prompt blood pressure control now appears desi-
rable in order to beneﬁ t maximally from the blood pressure 
lowering (Julius et al 2004). Admittedly, the current way to 
analyze results of clinical trials in the ﬁ eld of hypertension 
does not enable assessment of how difﬁ cult or easy it is to 
normalize blood pressure in the individual patient. This 
prompted us to test whether a score system integrating the 
evolution of efﬁ cacy and tolerability over time would facili-
tate the weighing of advantages and disadvantages of diffe-
rent therapeutic strategies, and therefore render comparison 
between them more meaningful. For this purpose we used 
the observations obtained in the STRATHE trial. A better 
score was seen in the patients allocated to the ﬁ xed low-dose 
combination compared with the two other options. Notably, 
the number of points given to efﬁ cacy and tolerability cri-
teria could be attributed differently in other clinical trials, 
depending, on the relative importance one wants to give to 
the various criteria to be taken into account.
In summary, it is possible to analyze the results of trials 
aimed to compare different treatment strategies in the ﬁ eld 
of hypertension using a score system. This approach gives an 
integrative view on the evolution of efﬁ cacy and tolerability, 
and reﬂ ects how difﬁ cult or easy it is to normalize blood 
pressure. Further studies are, however, needed to test pros-
pectively whether this type of analysis is more informative 
than an analysis based on efﬁ cacy and tolerability criteria 
considered separately.
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